BLTE

Belite Bio is a classic clinical-stage biotech: zero revenue across five reported fiscal years (FY2021–FY2025), with net losses accelerating from -$9.67M in FY2021 to -$77.6M in FY2025. The FY2025 loss more than doubled YoY (-114.7%), driven by R&D spend that jumped 51.6% to $45.4M as the pipeline advances. With no product sales, every dollar of valuation is a bet on future clinical readouts.

The offsetting strength — and what makes this a hold rather than an avoid — is an unusually pristine balance sheet. Cash and equivalents exploded 1,014% YoY to $353M, total assets grew 413% to $781M, and stockholders' equity reached $770M against just $10.1M of total liabilities (debt/equity effectively 0.01x). The 23.6% share-count increase to 39.3M suggests this cash was raised via equity, diluting holders but extending runway materially. Against FY2025 operating cash burn of -$37M, the cash pile implies multiple years of runway even if burn keeps climbing — a rare luxury for a pre-revenue biotech and a real downside cushion.